Cleviprex (Clevidipine Butyrate) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

No clinical drug interaction studies were conducted. Clevidipine and its major dihydropyridine metabolite do not have the potential for blocking or inducing any CYP enzyme.

OVERDOSAGE

There has been no experience of overdosage in human clinical trials. In clinical trials, doses of Cleviprex up to 106 mg/hour or 1153 mg maximum total dose were administered. The expected major effects of overdose would be hypotension and reflex tachycardia.

Discontinuation of Cleviprex leads to a reduction in antihypertensive effects within 5 to 15 minutes [see Clinical Pharmacology] . In case of suspected overdosage, Cleviprex should be discontinued immediately and the patient’s blood pressure should be supported.

CONTRAINDICATIONS

Known Allergy

Cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products.

Defective Lipid Metabolism

Cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.

Severe Aortic Stenosis

Cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery.